• Discovering & developing proprietary prodrugs

    Our products have improved properties over approved drugs and address unmet medical needs in large, established markets.

  • Creating a diverse pipeline of prodrug therapeutics

    We employ our LAT™ (Ligand Activated Therapy) technology to improve the attributes of approved drugs.

  • Decades of experience in devising elegant solutions

    KemPharm® continues to implement its LAT™ technology to create prodrugs that are new molecules by chemically attaching ligand(s) to the parent drug.

Products & Possibilities

Our co-lead clinical development candidates are KP415 – a prodrug product of dexmethylphenidate (d-MPH) with potential improvements over existing extended-release ADHD treatments, and KP484 – a “super-extended release” d-MPH prodrug product for the treatment of ADHD in patients that require a very long duration of therapy.

In addition, we have gained approval of Apadaz®, an immediate-release, benzhydrocodone/acetaminophen combination product for the treatment of acute pain. 

Our Value Proposition

KemPharm® believes that its LAT™ technology offers potential benefits to improve drug properties by developing prodrugs that are new molecules with improved attributes over FDA-approved drugs, such as enhanced bioavailability, extended duration of action, increased safety, and reduced susceptibility to abuse.

Learn More

KemPharm’s pipeline consists of multiple programs targeting opportunities in ADHD, pain, and CNS indications.

We employ our LAT™ (Ligand Activated Therapy) technology to improve the attributes of approved drugs.

Learn more about LAT™

May 4, 2020

Featured Publication

NDA Filing for Potential New ADHD Treatment, KP415, Accepted by FDA; KemPharm Eligible to Receive $5 Million Milestone Payment from Gurnet Point Capital

Corium, GPC’s portfolio company, to lead all commercialization activities for KP415 Celebration, FL – May 4, 2020 – KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today confirmed that the U.S. Food and Drug Administration (FDA) has accepted the New Drug […]

keep reading

KemPharm® Company Overview
KemPharm® Company Culture

  • 19

    May

    20

  • KemPharm Receives Day-74 Letter for KP415 NDA

  • 12

    May

    20

  • KemPharm Reports First Quarter 2020 Financial...

  • 06

    May

    20

  • KemPharm to Report First Quarter 2020 Financi...